What does sale of european ORLADEYO business mean?

Represents the financial impact of divesting a specific regional business unit on the company's overall tax position. This metric captures the tax consequences, such as gains or losses on sale, that influence the effective tax rate. It is used to evaluate the tax efficiency of strategic portfolio restructuring activities.

BioCryst Pharmaceuticals BCRX Sale of European ORLADEYO business

Sale of European ORLADEYO business at other companies

GE VernovaGEV

-$48.25M—

VestisVSTS

0%—

The J.M. Smucker CompanySJM

$0+100%

Cleveland-CliffsCLF

$0—

Willis Towers WatsonWTW

$46.75M+3,217%

WingstopWING

-$5.11M—

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDisposalOfBusinessAmount.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's sale of european orladeyo business.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's sale of european ORLADEYO business?: BioCryst Pharmaceuticals (BCRX) reported sale of european ORLADEYO business of $966.75K in Q4 2025.
What does sale of european ORLADEYO business mean?: Represents the financial impact of divesting a specific regional business unit on the company's overall tax position. This metric captures the tax consequences, such as gains or losses on sale, that influence the effective tax rate. It is used to evaluate the tax efficiency of strategic portfolio restructuring activities.